Ljn452, 0,1 mg    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
93原発性胆汁性胆管炎[原発性胆汁性肝硬変 (~2017.3)]1

93. 原発性胆汁性胆管炎[原発性胆汁性肝硬変 (~2017.3)] [臨床試験数:230,薬物数:215(DrugBank:51),標的遺伝子数:34,標的パスウェイ数:107
Searched query = "Primary biliary cholangitis", "Primary biliary cirrhosis", "PBC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 230 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-001590-41-DE
(EUCTR)
11/01/201613/01/2016A multi-part, double blind study to assess safety, tolerability and efficacy of tropifexor (LJN452) in PBC patientsA multi-part, randomized, double-blind, placebo-controlled study to assess the safety, tolerability and efficacy of tropifexor (LJN452) in patients with primary biliary cholangitis - Multi-part, double blind study to assess safety, tolerability and efficacy of LJN452 in PBC patients primary biliary cholangitis
MedDRA version: 20.1;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Code: LJN452, 0,01 mg
INN or Proposed INN: tropifexor
Other descriptive name: LJN452
Product Code: LJN452, 0,03 mg
INN or Proposed INN: tropifexor
Other descriptive name: LJN452
Product Code: LJN452, 0,1 mg
INN or Proposed INN: tropifexor
Other descriptive name: LJN452
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
152Phase 2United States;Canada;Poland;Russian Federation;Germany;China;United Kingdom